Navigation Links
MDS Pharma Services Names Dr. Lori McDonald to Executive Leadership Team

Experienced leader will head Quality & Compliance function at leading

contract research organization

KING OF PRUSSIA, PA, June 26 /PRNewswire-FirstCall/ - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, has hired Dr. Lori McDonald as Vice President, Quality & Compliance. Dr. McDonald will lead MDS Pharma Services' ongoing program to build and manage quality and regulatory compliance systems across its global business platforms.

"I'm delighted that Dr. McDonald has joined our leadership team," said MDS Pharma Services President David Spaight. "By enabling process improvements and compliance with regulatory requirements, she and her staff will be instrumental in helping MDS Pharma Services deliver high-quality, on-time services. This will help our clients expedite their drug discovery and development programs."

Dr. McDonald brings strong credentials to this key leadership position. Before joining MDS she served as Vice President, Regulatory Affairs with Alder Biopharmaceuticals. From 2001 to 2006, Dr. McDonald held a series of leadership roles with Cardinal Health, culminating as Executive Director, Regulatory Affairs. Prior to that, she worked at Ligand Pharmaceuticals and Abbott Laboratories.

Dr. McDonald holds a B.S. in Medical Technology from the University of North Dakota, and both an M.S. and a Ph. D. in Pharmaceutics from the University of Michigan. She also holds a Regulatory Affairs Certification, which is administered by the Regulatory Affairs Professionals Society.

About MDS Pharma Services

MDS Pharma Services is committed to delivering quality service on time. We offer a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, we apply advanced scientific and technological expertise throughout the drug discovery and development process - from lead optimization, pre-IND research, early clinical research (bioequivalence, phases I-IIa) and bioanalysis through to global clinical development (phases IIb-IV), central lab and centralized cardiac services. For more information, visit our website at

MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ), a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,500 highly skilled people in 29 countries. Find out more at or by calling 1-888-MDS-7222, 24 hours a day.

SOURCE MDS Pharma Services
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program
2. KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission
3. Fischman receives Pharmacology/Therapeutics/Toxicology Research Award
4. Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index
5. Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards
6. CEVA Logistics Awarded Best 3PL Provider for Pharmaceutical, Chemical, HazMat and Fresh Food Supply Chains
7. NACDS Praises House Legislation to Delay Medicaid Cuts, Aid Pharmacies in Treating Patients
8. The MedZilla Report: May 2008 Employment Outlook for Biotech/Pharma/Health
9. 1 step closer to green chemistry and improved pharmaceuticals
10. Pharmavite Partners With LearnSomething, Inc. on Consumer Education Program, LearnSomethingAbout(TM)
11. MAP Pharmaceuticals Acquires Proprietary Drug Particle Formulation Technology From Eiffel/Telesso Technologies Limited
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: